Ranitidine (Ebunazi, Ebunaziinjection)
Ranitidine
Bliss Pharmaceuticals (Pty) Ltd
Registration
- Applicant
- Bliss Pharmaceuticals (Pty) Ltd
- Registrations
- 3
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Ebunazi 150 tablets EACH TABLET CONTAINS RANITIDINE HYDROCHLORIDE EQUIVALENT TO 150 MG RANITIDINE | 150Tablets | 28002328/11.4.3/0023 | Registered | Not determined | None |
| Ebunazi 300 tablets EACH TABLET CONTAINS RANITIDINE HYDROCHLORIDE 336 MG EQUIVALENT TO 300 MG RANITIDINE | 300Tablets | 28002428/11.4.3/0024 | Registered | Not determined | None |
| Ebunaziinjection EACH 2 ML CONTAINS RANITIDINE HYDROCHLORIDE 56 MG EQUIVALENT TO 50 MG RANITIDINE | Not listed | 28009528/11.4.3/0095 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S3: Ranitidine
- except where administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to a maximum dose of 75 milligrams, a maximum daily dose of 300 milligrams and a maximum treatment period of two weeks. (S2)
Consolidated Schedules 06 July 2026, lines 4205 to 4207
S2: Ranitidine
- when administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to -
- a maximum dose of 75 milligrams;
- a maximum daily dose of 300 milligrams;
- a maximum treatment period of two weeks. (S3)
Consolidated Schedules 06 July 2026, lines 2625 to 2632
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(E)-1-N'-[2-[[5-[(Dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine
Drag to rotate. Structure from PubChem CID 3001055.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.